217 related articles for article (PubMed ID: 35807457)
1. The Nucleoside/Nucleotide Analogs Tenofovir and Emtricitabine Are Inactive against SARS-CoV-2.
Feng JY; Du Pont V; Babusis D; Gordon CJ; Tchesnokov EP; Perry JK; Duong V; Vijjapurapu A; Zhao X; Chan J; Cohen C; Juneja K; Cihlar T; Götte M; Bilello JP
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807457
[TBL] [Abstract][Full Text] [Related]
2. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Nomah DK; Reyes-Urueña J; Díaz Y; Moreno S; Aceiton J; Bruguera A; Vivanco-Hidalgo RM; Casabona J; Domingo P; Navarro J; Imaz A; Deig E; Navarro G; Llibre JM; Miro JM;
J Antimicrob Chemother; 2022 Jul; 77(8):2265-2273. PubMed ID: 35678461
[TBL] [Abstract][Full Text] [Related]
3. Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.
Del Amo J; Polo R; Moreno S; Martínez E; Cabello A; Iribarren JA; Curran A; Macías J; Montero M; Dueñas C; Mariño AI; de la Cámara SP; Díaz A; Arribas JR; Jarrín I; Hernán MA;
AIDS; 2022 Dec; 36(15):2171-2179. PubMed ID: 36382436
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
5. Comparative Antiviral Activity of Remdesivir and Anti-HIV Nucleoside Analogs Against Human Coronavirus 229E (HCoV-229E).
Parang K; El-Sayed NS; Kazeminy AJ; Tiwari RK
Molecules; 2020 May; 25(10):. PubMed ID: 32429580
[TBL] [Abstract][Full Text] [Related]
6. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects.
Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir alafenamide (TAF) does not deplete mitochondrial DNA in human T-cell lines at intracellular concentrations exceeding clinically relevant drug exposures.
Stray KM; Park Y; Babusis D; Callebaut C; Cihlar T; Ray AS; Perron M
Antiviral Res; 2017 Apr; 140():116-120. PubMed ID: 28131805
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV.
Li G; Park LS; Lodi S; Logan RW; Cartwright EJ; Aoun-Barakat L; Casas JP; Dickerman BA; Rentsch CT; Justice AC; Hernán MA
AIDS; 2022 Oct; 36(12):1689-1696. PubMed ID: 35848570
[TBL] [Abstract][Full Text] [Related]
9. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
[TBL] [Abstract][Full Text] [Related]
10. Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
Yager JL; Brooks KM; Castillo-Mancilla JR; Nemkov C; Morrow M; Peterson S; Ibrahim M; Bushman L; Kiser JJ; MaWhinney S; Anderson PL
AIDS; 2021 Dec; 35(15):2481-2487. PubMed ID: 34482350
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
12. Antiviral Activity of Tenofovir Alafenamide against HIV-1 with Thymidine Analog-Associated Mutations and M184V.
Margot N; Ram R; Abram M; Haubrich R; Callebaut C
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31988104
[TBL] [Abstract][Full Text] [Related]
13. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
14. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
15. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
16. Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
Cox S; Margot N; Callebaut C
J Med Virol; 2023 Apr; 95(4):e28723. PubMed ID: 37185867
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women.
Hodder S; Squires K; Kityo C; Hagins D; Avihingsanon A; Kido A; Jiang S; Kulkarni R; Cheng A; Cao H
J Acquir Immune Defic Syndr; 2018 Jun; 78(2):209-213. PubMed ID: 29481486
[TBL] [Abstract][Full Text] [Related]
18. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Margot NA; Kitrinos KM; Fordyce M; McCallister S; Miller MD; Callebaut C
HIV Clin Trials; 2016 Mar; 17(2):78-87. PubMed ID: 26892863
[TBL] [Abstract][Full Text] [Related]
19. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort.
Berenguer J; Díez C; Martín-Vicente M; Micán R; Pérez-Elías MJ; García-Fraile LJ; Vidal F; Suárez-García I; Podzamczer D; Del Romero J; Pulido F; Iribarren JA; Gutiérrez F; Poveda E; Galera C; Izquierdo R; Asensi V; Portilla J; López JC; Arribas JR; Moreno S; González-García J; Resino S; Jarrín I
Clin Microbiol Infect; 2021 Nov; 27(11):1678-1684. PubMed ID: 34186209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
